These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 15363200)

  • 1. [Relationship between the expression of O6-methylguanine-DNA methyltransferase in glioma and the survival time of patients].
    Sun YH; Zhang YZ; Wang ZC; Sun MZ; Zhao DH
    Ai Zheng; 2004 Sep; 23(9):1052-5. PubMed ID: 15363200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort.
    Pollack IF; Hamilton RL; Sobol RW; Burnham J; Yates AJ; Holmes EJ; Zhou T; Finlay JL
    J Clin Oncol; 2006 Jul; 24(21):3431-7. PubMed ID: 16849758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
    Capper D; Mittelbronn M; Meyermann R; Schittenhelm J
    Acta Neuropathol; 2008 Feb; 115(2):249-59. PubMed ID: 17965865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
    Brell M; Tortosa A; Verger E; Gil JM; Viñolas N; Villá S; Acebes JJ; Caral L; Pujol T; Ferrer I; Ribalta T; Graus F
    Clin Cancer Res; 2005 Jul; 11(14):5167-74. PubMed ID: 16033832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
    Heimberger AB; McGary EC; Suki D; Ruiz M; Wang H; Fuller GN; Bar-Eli M
    Clin Cancer Res; 2005 Jan; 11(1):267-72. PubMed ID: 15671555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].
    Huang L; Jiang T; Yuan F; Li GL; Xu LX; Cui Y
    Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):752-8. PubMed ID: 22335907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity in the expression of markers for drug resistance in brain tumors.
    Andersson U; Malmer B; Bergenheim AT; Brännström T; Henriksson R
    Clin Neuropathol; 2004; 23(1):21-7. PubMed ID: 14986930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics.
    Silber JR; Bobola MS; Ghatan S; Blank A; Kolstoe DD; Berger MS
    Cancer Res; 1998 Mar; 58(5):1068-73. PubMed ID: 9500473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between O6-methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients.
    Chen ZP; Yarosh D; Garcia Y; Tampieri D; Mohr G; Malapetsa A; Langleben A; Panasci LC
    Can J Neurol Sci; 1999 May; 26(2):104-9. PubMed ID: 10352868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of O6-methylguanine-DNA methyltransferase in soft tissue sarcomas: association with K-ras mutations.
    Kim JI; Suh JT; Choi KU; Kang HJ; Shin DH; Lee IS; Moon TY; Kim WT
    Hum Pathol; 2009 Jul; 40(7):934-41. PubMed ID: 19356788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.
    Eoli M; Menghi F; Bruzzone MG; De Simone T; Valletta L; Pollo B; Bissola L; Silvani A; Bianchessi D; D'Incerti L; Filippini G; Broggi G; Boiardi A; Finocchiaro G
    Clin Cancer Res; 2007 May; 13(9):2606-13. PubMed ID: 17473190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
    Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
    Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation of hTERT expression to maspin and bFGF expression and their significance in glioma].
    Wang DL; Wang YF; Shi GS; Huang H
    Ai Zheng; 2007 Jun; 26(6):601-6. PubMed ID: 17562265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis.
    Sasai K; Nodagashira M; Nishihara H; Aoyanagi E; Wang L; Katoh M; Murata J; Ozaki Y; Ito T; Fujimoto S; Kaneko S; Nagashima K; Tanaka S
    Am J Surg Pathol; 2008 Aug; 32(8):1220-7. PubMed ID: 18580490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of tetraspanin CD151 in newly diagnosed glioblastomas.
    Lee D; Suh YL; Park TI; Do IG; Seol HJ; Nam DH; Kim ST
    J Surg Oncol; 2013 May; 107(6):646-52. PubMed ID: 22926763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas.
    Nakagawa T; Ido K; Sakuma T; Takeuchi H; Sato K; Kubota T
    Neuropathology; 2009 Aug; 29(4):379-88. PubMed ID: 19019175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy.
    Silber JR; Blank A; Bobola MS; Ghatan S; Kolstoe DD; Berger MS
    Clin Cancer Res; 1999 Apr; 5(4):807-14. PubMed ID: 10213216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
    Zhang JP; Shi HL; Sai K; Yue WY; Mu YG; Zhang XH; Chen ZP
    Ai Zheng; 2006 Dec; 25(12):1533-7. PubMed ID: 17166381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of O6-methylguanine-DNA methyltransferase gene expression in gliomas by platinum compounds.
    Tanaka S; Kobayashi I; Utsuki S; Oka H; Yasui Y; Fujii K
    Oncol Rep; 2005 Nov; 14(5):1275-80. PubMed ID: 16211296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas--correlation with array comparative genome hybridization results and IDH1 mutation.
    Tuononen K; Tynninen O; Sarhadi VK; Tyybäkinoja A; Lindlöf M; Antikainen M; Näpänkangas J; Hirvonen A; Mäenpää H; Paetau A; Knuutila S
    Genes Chromosomes Cancer; 2012 Jan; 51(1):20-9. PubMed ID: 21922591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.